The Traderszone Network

Published in TZ Latest News 28 June, 2021 by The TZ Newswire Staff

Why Beam Therapeutics Jumped Today

Beam Therapeutics (NASDAQ: BEAM) was up 14% midday Monday on the back of Intellia Therapeutics‘ (NASDAQ: NTLA) phase 1 data for its therapy to treat a genetic liver disorder.

All of the companies associated with the gene-editing technique are having a good day thanks to the data. Although the treatment for the fatal disease — transthyretin (ATTR) amyloidosis — is great news, the implications go far beyond any one disease.

read more